This article is more than 5 years old. Information may no longer be current.
Glaukos reports second quarter net loss
Click Here to Manage Email Alerts
Glaukos reported a net loss of $6.3 million, or $0.17 per share, for the second quarter of 2019 compared with a net loss of $5.4 million, or $0.15 per share, for the same period a year ago, according to a press release.
Net sales increased from $43.2 million to $58.6 million.
Selling, general and administrative expenses increased from $28.6 million to $37.7 million, while research and development expenses increased from $12.6 million to $17 million. The higher expenses were attributed to growth in global commercial infrastructure, increases in administrative personnel and expenses, spending associated with research, clinical trials and enterprise systems integration, and a one-time R&D supplier agreement charge.
Glaukos had cash, cash equivalents, short-term investments and restricted cash of $159.2 million as of June 30.